Loading...
XSHG
603456
Market cap2.20bUSD
Jul 28, Last price  
17.89CNY
1D
3.89%
1Q
28.52%
Jan 2017
49.33%
IPO
163.48%
Name

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
15.30
P/S
2.86
EPS
1.17
Div Yield, %
2.79%
Shrs. gr., 5y
2.54%
Rev. gr., 5y
24.29%
Revenues
5.52b
+1.44%
590,669,767652,528,857833,378,939935,110,2281,143,419,7501,309,584,2041,286,206,7661,444,511,0851,653,177,2101,717,440,5991,862,225,1582,016,815,8532,647,284,1634,063,181,9155,445,105,1545,523,418,175
Net income
1.03b
+12.17%
41,423,75267,211,243109,859,779117,049,728136,256,784166,240,814133,278,522200,079,304111,480,460147,605,263157,147,456237,793,378380,584,950633,900,939921,170,3701,033,255,687
CFO
1.36b
+10.98%
82,841,684122,025,843105,299,432111,006,749154,281,690203,861,15310,167,664140,525,669136,646,433244,201,283264,782,500554,161,971400,392,398677,519,2361,225,782,0921,360,323,930
Dividend
Jul 04, 20240.5 CNY/sh
Earnings
Aug 25, 2025

Profile

Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
URL
http://www.jiuzhoupharma.com
IPO date
Oct 10, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,523,418
1.44%
5,445,105
34.01%
Cost of revenue
4,017,233
3,999,154
Unusual Expense (Income)
NOPBT
1,506,185
1,445,952
NOPBT Margin
27.27%
26.56%
Operating Taxes
149,270
183,272
Tax Rate
9.91%
12.67%
NOPAT
1,356,915
1,262,680
Net income
1,033,256
12.17%
921,170
45.32%
Dividends
(358,649)
(208,575)
Dividend yield
1.66%
0.59%
Proceeds from repurchase of equity
(65,287)
BB yield
0.30%
Debt
Debt current
7,768
256,854
Long-term debt
412,839
105,187
Deferred revenue
109,116
101,196
Other long-term liabilities
50,767
25,757
Net debt
(2,907,698)
(848,509)
Cash flow
Cash from operating activities
1,360,324
1,225,782
CAPEX
(929,442)
Cash from investing activities
(1,056,803)
Cash from financing activities
2,102,185
FCF
174,268
862,927
Balance
Cash
3,206,427
1,095,426
Long term investments
121,877
115,124
Excess cash
3,052,133
938,295
Stockholders' equity
3,864,621
3,407,502
Invested Capital
6,049,532
4,806,061
ROIC
25.00%
27.87%
ROCE
16.37%
24.71%
EV
Common stock shares outstanding
890,738
829,660
Price
24.21
-42.94%
42.43
-24.58%
Market cap
21,564,759
-38.74%
35,202,459
-24.98%
EV
18,728,999
34,428,871
EBITDA
1,888,004
1,794,149
EV/EBITDA
9.92
19.19
Interest
25,208
22,376
Interest/NOPBT
1.67%
1.55%